Table 2 Univariate and multivariate analyses of prognostic factors in patients with metastatic pancreatic cancer
From: Circulating CD8+CD122+ T cells as a prognostic indicator of pancreatic cancer
Covariate (n=54) | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value | |
Sex (Male) | 1.51 | 0.75–3.07 | 0.25 |  |  |  |
Age (≥65 years) | 1.80 | 0.83–3.93 | 0.14 |  |  |  |
Diabetes mellitus (yes) | 0.70 | 0.34–1.42 | 0.32 | 0.34 | 0.15–0.75 | 0.0076 |
Serum albumin (g/dL) | ||||||
 ≥3.5 | 1.22 | 0.56–2.66 | 0.61 | 2.83 | 1.11–7.26 | 0.030 |
ECOG performance status | ||||||
 1–2/0 | 2.02 | 0.99–4.13 | 0.054 | 4.67 | 1.92–11.32 | 0.0007 |
1st line chemotherapy | ||||||
 mFFX/GnP | 0.80 | 0.30–2.11 | 0.65 |  |  |  |
 GnP/S-IROX | 0.81 | 0.11–6.14 | 0.84 |  |  |  |
 mFFX/S-IROX | 0.65 | 0.08–5.74 | 0.70 |  |  |  |
T factor | ||||||
 4/1–3 | 0.52 | 0.24–1.14 | 0.10 |  |  |  |
CA19-9 level (U/mL) | ||||||
 ≥1000 | 2.90 | 1.37–6.12 | 0.005 | 3.29 | 1.51–7.18 | 0.0028 |
CD4+ T cell level (%) | ||||||
 High | 0.45 | 0.22–0.92 | 0.030 | 0.35 | 0.15–0.78 | 0.011 |